3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Unknown
1
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia
1
Glioblastoma
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
Cyclophosphamide
27
Rituximab
20
Etoposide
14
Cytarabine
13
Melphalan
11
Vincristine
10
fludarabine
9
Prednisone
9
Doxorubicin
9
Busulfan
8
Peripheral Blood Stem Cell Transplantation
7
Radiotherapy
6
Filgrastim
6
Cyclosporine
6
Bendamustine Hydrochloride
6
fludarabine phosphate
5
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
5
Mycophenolic Acid
5
Cisplatin
5
tositumomab I-131
4
ibritumomab tiuxetan
4
Ifosfamide
4
Dexamethasone
4
Carmustine
4
relmacabtagene autoleucel
3
Thiotepa
3
Indium
3
Immunotherapy, Adoptive
3
Gemcitabine
3
Drug Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Lymphoma, Non-Hodgkin
×
Antibodies, Monoclonal
×
Clear all
NCT00515892
2007-08-14
NHL
Cambridge Antibody Technology
Phase 1
Unknown
50 enrolled